ER
TNDM icon

Enlightenment Research’s Tandem Diabetes Care TNDM Stock Holding History

Enlightenment Research’s Portfolio TNDM Stock Details TNDM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-14,400
Closed -$884K – 263
2019
Q2 		$884K Buy
+14,400
New +$929K 0.45% 55

Other funds holding TNDM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Enlightenment Research's TNDM Position: Q3 2019 in Review

Enlightenment Research sold out of Tandem Diabetes Care (TNDM) in Q3 2019, closing a stake of 14,400 shares — an estimated $884K sold.

Enlightenment Research first reported a position in TNDM in Q2 2019 and held it in 1 quarter. The position peaked at $884K in Q2 2019. 273 funds tracked by Wall St. Rank hold TNDM as of Q3 2019.

  • Enlightenment Research reported no remaining Tandem Diabetes Care position as of Q3 2019 after selling out during the quarter.
  • Enlightenment Research sold 14,400 Tandem Diabetes Care shares in Q3 2019, an estimated $884K.
  • Enlightenment Research first reported a position in Tandem Diabetes Care in Q2 2019 and held it in 1 quarter.
  • Enlightenment Research's Tandem Diabetes Care position peaked at $884K in Q2 2019.
  • 273 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q3 2019.

Based on Enlightenment Research's 13F filing for Q3 2019, filed 16 Oct 2019.